Inhibition of MAO activity, 3H-imipramine binding, 3H-paroxetine binding and 3H-5-HT uptake by human cerebrospinal fluid

  • T. Egashira
  • S. Goto
  • F. Murayama
  • Y. Yamanaka
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)


Addition of small amount of human cerebrospinal fluid (CSF) inhibited both types of MAO in monkey brain mitochondria. The specific binding of 3H-paroxetine decreased remarkably with increasing CSF volumes, while 3H-imipramine binding was slightly inhibited. Scatchard analysis of 3H-paroxetine binding in the presence and absence of CSF indicated that the inhibitory effect was associated with a decreased Bmax without an appreciable change in Kd. Addition of CSF induced an inhibition of uncompetitive 3H-5-HT uptake to monkey cerebral membranes. These results indicate that the materials in human CSF inhibit 3H-paroxetine binding, and modulate the uptake system for 5-HT.


Scatchard Analysis Serotonin Uptake Monkey Brain Paroxetine Binding Imipramine Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abraham KI, Ieni JR, Meyerson LR (1987) Purification and properties of a human plasma endogenous modulator for the platelet tricyclic binding/serotonin transport complex. Biochim Biophys Acta 923:8–21.PubMedCrossRefGoogle Scholar
  2. Angel I, Paul SM (1984) Inhibition of synaptosomal 5-3H-hydroxytryptamine uptake by endogenous factor(s) in human blood. FEBS Lett 171:280–284.PubMedCrossRefGoogle Scholar
  3. Barbaccia ML, Gandolfi O, Chuang DH, Costa E (1983) Modulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine recognition sites. Proc Natl Acad Sci USA 80:5134–5138.PubMedCrossRefGoogle Scholar
  4. Barkai AI, Baron M, Kowalik S, Cooper B (1986) Inhibition of 3H-imipramine binding by plasma from depressed and normal subjects. Psychiatry Res 17:261–267.PubMedCrossRefGoogle Scholar
  5. Becker RE, Giambalvo CT, Fox RA, Macho M (1983) Endogenous inhibitors of monoamine oxidase present in human cerebrospinal fluid. Science 221:476–478.PubMedCrossRefGoogle Scholar
  6. Berrettini WH, Vogel WH (1978) Evidence for an endogenous inhibitor of platelet MAO in chronic schizophrenia. Am J Psychiatry 135:605–607.PubMedGoogle Scholar
  7. Briley M, Langer SZ, Sette M (1982) Allosteric interaction between the 3H-imipramine binding site and the serotonin uptake mechanism. Br J Pharmacol 74:817–818.Google Scholar
  8. Brusov OS, Fomenko AM, Katasonov AB (1985) Human plasma inhibitors of platelet serotonin uptake and imipramine receptor binding: extraction and heterogeneity. Biol Psychiatry 20:235–244.PubMedCrossRefGoogle Scholar
  9. Carlsson A, Fuxe K, Ungerstedt U (1968) The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol 20:150–151.PubMedCrossRefGoogle Scholar
  10. Davidson JRT, Mcleod MN, Turnbull CD, White HL, Feuer EJ (1980) Platelet monoamine oxidase activity and the classification of depression. Arch Gen Psychiatry 37:771–773.PubMedCrossRefGoogle Scholar
  11. Egashira T, Yamamoto T, Yamanaka Y (1984) Some interrelated properties of A and B form monoamine oxidase in monkey brain mitochondria. Jpn J Pharmacol 34:327–334.PubMedCrossRefGoogle Scholar
  12. Egashira T, Takano R, Yamanaka Y (1986) Demonstration of endogenous inhibitors of monoamine oxidase in dog cerebrospinal fluid. Jpn J Pharmacol 42:583–586.PubMedCrossRefGoogle Scholar
  13. Egashira T, Takano R, Yamanaka Y (1987) Modulation of neuronal MAO activity, 5-HT uptake and imipramine binding by endogenous substances in dog cerebrospinal fluid. Biochem Pharmacol 36:1781–1785.PubMedCrossRefGoogle Scholar
  14. Giambalvo CT (1984) Purification of endogenous modulators of monoamine oxidase from plasma. Biochem Pharmacol 33:3929–3932.PubMedCrossRefGoogle Scholar
  15. Glover V, Reveley MA, Sandier M (1980) A monoamine oxidase inhibitor in human urine. Biochem Pharmacol 29:467–470.PubMedCrossRefGoogle Scholar
  16. Habert E, Graham D, Tahraoui L, Claustre Y, Langer SZ (1985) Characterization of 3H-paroxetine binding to rat cortical membranes. Eur J Pharmacol 118:107–114.PubMedCrossRefGoogle Scholar
  17. Kinnier WJ, Chuang DM, Gwynn G, Cost E (1981) Characteristics and regulation of high affinity 3H-imipramine binding to rat hippocampal membranes. Neuropharmacology 20:411–419.PubMedCrossRefGoogle Scholar
  18. Langer SZ, Raisman R, Tahraoui L, Scatton B, Niddam R, Lee CR, Claustre Y (1984) Substituted tetrahydro-β-carbolines are possible candidates as endogenous ligand of the 3H-imipramine recognition site. Eur J Pharmacol 98:153–154.PubMedCrossRefGoogle Scholar
  19. Lindbrink P, Jonsson G, Fuxe K (1971) The effect of imipramine like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacology 10:521–536.CrossRefGoogle Scholar
  20. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265–275.PubMedGoogle Scholar
  21. Magnussen I, Tonderk K, Engback F (1982) Paroxetine, a potent selective longacting inhibitor of synaptosomal 5-HT uptake in mice. J Neural Transm 55:217–226.CrossRefGoogle Scholar
  22. Mellerup ET, Plenge P, Engelstoft M (1984) High affinity binding of 3H-paroxetine and 3H-imipramine to human platelet membranes. Eur J Pharmacol 96:303–309.CrossRefGoogle Scholar
  23. Mellerup ET, Plenge P, Nielsen M (1985) Size determination of binding polymers for 3H-imipramine and 3H-paroxetine in human platelet membranes. Eur J Pharmacol 106:411–413.CrossRefGoogle Scholar
  24. Miron B, Levitt M, Perlman R (1980) Low platelet monoamine oxidase activity: a possible biochemical correlate of borderline schizophrenia. Psychiatry Res 3:329–336.CrossRefGoogle Scholar
  25. Oreland L, Wiberg A, Askerg A, Traskman L, Sjostand L, Thoren P, Bertilsson L, Tybring G (1981) Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and succidal patients and healthy controls. Psychiatry Res 4:21–30.PubMedCrossRefGoogle Scholar
  26. Raisman R, Briley M, Langer SZ (1979) Specific tricyclic antidepressant binding sites in rat brain. Nature 281:148–150.PubMedCrossRefGoogle Scholar
  27. Rehavi M, Ventura I, Sarne Y (1985) Demonstration of endogenous imipramine like material in rat brain. Life Sci 36:687–693.PubMedCrossRefGoogle Scholar
  28. Ross SB, Renyi AL (1975) Tricyclic antidepressant agents I. Comparison of the inhibition of the uptake of 3H-noradrenaline and 14C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain, hypothalamus regions of the rat brain. Acta Pharmacol Toxicol 36:382–394.Google Scholar
  29. Wennogle LP, Meyerson LR (1985) Serotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelet membranes. Life Sci 36:1541–1550.PubMedCrossRefGoogle Scholar
  30. Yu PH, Boulton AA (1977) Activation of platelet monoamine oxidase by plasma in the human. Life Sci 25:31–36.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • T. Egashira
    • 1
  • S. Goto
    • 1
  • F. Murayama
    • 1
  • Y. Yamanaka
    • 1
  1. 1.Department of PharmacologyMedical College of OitaHazama-cho, OitaJapan

Personalised recommendations